Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTSepterna, Inc.'s latest supported as-filed period reports revenue of $26.7M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -82.92% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 22375.63% · CORE
Level · gp.fundamentals.operating_margin
Raw value -62.95% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 131.35% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 18.97% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue changed across a low base; Operating margin moved 2428831 bp higher; Operating income increased 41.9%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 55.3%; Operating cash flow decreased 9.3%.
2 evidence-backed componentsOperating income changed +41.9% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
SEPN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-388033SEC ↗4Sep 3, 2026Period Sep 1, 20260001193125-26-382267SEC ↗8-KAug 25, 2026Period Aug 22, 20260001193125-26-364210SEC ↗4Aug 14, 2026Period Aug 12, 20260001193125-26-352692SEC ↗4Aug 14, 2026Period Aug 12, 20260001231919-26-000938SEC ↗4Aug 13, 2026Period Aug 11, 20260001193125-26-349810SEC ↗10-QAug 10, 2026Period Jun 30, 20260001193125-26-342353SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 8, 2026Filed Sep 10, 2026 | Patni RajivChief Medical Officer | Grant Or AwardDirect | 275,000 | $0 | $0 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Long Daniel D.SVP, Drug Discovery | Option ExerciseDirect | 3,333 | $3 | $9,199 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Long Daniel D.SVP, Drug Discovery | Open Market SaleDirect | 3,333 | $38 | $126,078 | Form 4 ↗ |
| Sep 1, 2026Filed Sep 3, 2026 | Long Daniel D.SVP, Drug Discovery | Option ExerciseDirect | 3,333 | $0 | $0 | Form 4 ↗ |
| Aug 12, 2026Filed Aug 14, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed +2428831 basis points from the comparable as-filed period.
Research & development changed +58.3% from the comparable as-filed period.
Cash & equivalents changed -55.3% from the comparable as-filed period.
Capex / revenue changed -4874 basis points from the comparable as-filed period.
Current liabilities changed +424.3% from the comparable as-filed period.
Stock-based compensation changed +181.0% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-342328| Third Rock Ventures V, L.P.Reporting owner |
| Open Market SaleDirect |
| 147,059 |
| $50 |
| $7.4M |
| Form 4 ↗ |
| Aug 12, 2026Filed Aug 14, 2026 | Third Rock Ventures V, L.P.Reporting owner | Open Market SaleDirect | 141 | $51 | $7,202 | Form 4 ↗ |